0000950170-24-075625.txt : 20240620 0000950170-24-075625.hdr.sgml : 20240620 20240620163006 ACCESSION NUMBER: 0000950170-24-075625 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240617 FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Silverman Peter B. CENTRAL INDEX KEY: 0001790314 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37773 FILM NUMBER: 241056694 MAIL ADDRESS: STREET 1: C/O MERUS N.V. STREET 2: YALELAAN 62 CITY: UTRECHT STATE: P7 ZIP: 3584 CM ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Merus N.V. CENTRAL INDEX KEY: 0001651311 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: YALELAAN 62 CITY: 3584 CM UTRECHT STATE: P7 ZIP: 3584 CM BUSINESS PHONE: 31 030 253 8800 MAIL ADDRESS: STREET 1: YALELAAN 62 CITY: 3584 CM UTRECHT STATE: P7 ZIP: 3584 CM FORMER COMPANY: FORMER CONFORMED NAME: Merus B.V. DATE OF NAME CHANGE: 20150819 4 1 ownership.xml 4 X0508 4 2024-06-17 0001651311 Merus N.V. MRUS 0001790314 Silverman Peter B. C/O MERUS N.V. UPPSALALAAN 17 UTRECHT P7 3584 CT NETHERLANDS false true false false COO & GC true Common Shares 2024-06-17 4 M false 8423 25.90 A 8423 D Common Shares 2024-06-17 4 M false 41577 25.90 A 50000 D Common Shares 2024-06-17 4 M false 2747 17.94 A 52747 D Common Shares 2024-06-17 4 M false 9253 17.94 A 62000 D Common Shares 2024-06-17 4 S false 62000 56.519 D 0 D Share Option (right to buy) 25.90 2024-06-17 4 M false 8423 0.00 D 2027-02-15 Common Shares 8423 0 D Share Option (right to buy) 25.90 2024-06-17 4 M false 41577 0.00 D 2027-02-15 Common Shares 41577 0 D Share Option (right to buy) 17.94 2024-06-17 4 M false 2747 0.00 D 2028-02-21 Common Shares 2747 2547 D Share Option (right to buy) 17.94 2024-06-17 4 M false 9253 0.00 D 2028-02-21 Common Shares 9253 7453 D These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. The option is fully vested and exercisable. /s/ Peter Silverman 2024-06-20